

Xin Hu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7738347/publications.pdf>

Version: 2024-02-01

38
papers

1,708
citations

430874

18
h-index

315739

38
g-index

42
all docs

42
docs citations

42
times ranked

3595
citing authors

#	ARTICLE	IF	CITATIONS
1	A multiparametric calcium signal screening platform using iPSC-derived cortical neural spheroids.. SLAS Discovery, 2022, 27, 209-218.	2.7	8
2	The SARS-CoV-2 Cytopathic Effect Is Blocked by Lysosome Alkalinizing Small Molecules. ACS Infectious Diseases, 2021, 7, 1389-1408.	3.8	74
3	Discovery of TMPRSS2 Inhibitors from Virtual Screening as a Potential Treatment of COVID-19. ACS Pharmacology and Translational Science, 2021, 4, 1124-1135.	4.9	40
4	Application of niclosamide and analogs as small molecule inhibitors of Zika virus and SARS-CoV-2 infection. Bioorganic and Medicinal Chemistry Letters, 2021, 40, 127906.	2.2	15
5	Optimization of ether and aniline based inhibitors of lactate dehydrogenase. Bioorganic and Medicinal Chemistry Letters, 2021, 41, 127974.	2.2	2
6	Identification of Small Molecule Inhibitors of a Mir155 Transcriptional Reporter in Th17 Cells. Scientific Reports, 2021, 11, 11498.	3.3	2
7	Discovery of Small Molecule Entry Inhibitors Targeting the Fusion Peptide of SARS-CoV-2 Spike Protein. ACS Medicinal Chemistry Letters, 2021, 12, 1267-1274.	2.8	16
8	Hybrid <i>In Silico</i> Approach Reveals Novel Inhibitors of Multiple SARS-CoV-2 Variants. ACS Pharmacology and Translational Science, 2021, 4, 1675-1688.	4.9	6
9	Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening. ACS Pharmacology and Translational Science, 2020, 3, 1008-1016.	4.9	162
10	Quantum Dot-Conjugated SARS-CoV-2 Spike Pseudo-Virions Enable Tracking of Angiotensin Converting Enzyme 2 Binding and Endocytosis. ACS Nano, 2020, 14, 12234-12247.	14.6	88
11	Pyrazole-Based Lactate Dehydrogenase Inhibitors with Optimized Cell Activity and Pharmacokinetic Properties. Journal of Medicinal Chemistry, 2020, 63, 10984-11011.	6.4	30
12	Chlorcyclizine Inhibits Viral Fusion of Hepatitis C Virus Entry by Directly Targeting HCV Envelope Glycoprotein 1. Cell Chemical Biology, 2020, 27, 780-792.e5.	5.2	18
13	Synaptamide activates the adhesion GPCR GPR110 (ADGRF1) through GAIN domain binding. Communications Biology, 2020, 3, 109.	4.4	29
14	Small-molecule activation of lysosomal TRP channels ameliorates Duchenne muscular dystrophy in mouse models. Science Advances, 2020, 6, eaaz2736.	10.3	31
15	Discovery, Optimization, and Characterization of ML417: A Novel and Highly Selective D ₃ Dopamine Receptor Agonist. Journal of Medicinal Chemistry, 2020, 63, 5526-5567.	6.4	15
16	Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2. Frontiers in Pharmacology, 2020, 11, 592737.	3.5	69
17	Lead optimization and efficacy evaluation of quinazoline-based BET family inhibitors for potential treatment of cancer and inflammatory diseases. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1220-1226.	2.2	10
18	Discovery of novel inhibitors of human galactokinase by virtual screening. Journal of Computer-Aided Molecular Design, 2019, 33, 405-417.	2.9	14

#	ARTICLE	IF	CITATIONS
19	Identification of Chemotype Agonists for Human Resolvin D1 Receptor DRV1 with Pro-Resolving Functions. <i>Cell Chemical Biology</i> , 2019, 26, 244-254.e4.	5.2	25
20	Insights into the Action of Inhibitor Enantiomers against Histone Lysine Demethylase 5A. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 3193-3208.	6.4	9
21	Discovery of a Positive Allosteric Modulator of the Thyrotropin Receptor: Potentiation of Thyrotropin-Mediated Preosteoblast Differentiation In Vitro. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 364, 38-45.	2.5	14
22	Structure-Based Engineering of Irreversible Inhibitors against Histone Lysine Demethylase KDM5A. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 10588-10601.	6.4	28
23	Discovery and lead identification of quinazoline-based BRD4 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 3483-3488.	2.2	12
24	Optimization of the first small-molecule relaxin/insulin-like family peptide receptor (RXFP1) agonists: Activation results in an antifibrotic gene expression profile. <i>European Journal of Medicinal Chemistry</i> , 2018, 156, 79-92.	5.5	9
25	Emetine inhibits Zika and Ebola virus infections through two molecular mechanisms: inhibiting viral replication and decreasing viral entry. <i>Cell Discovery</i> , 2018, 4, 31.	6.7	128
26	Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 6364-6383.	6.4	12
27	Identification of 4-phenylquinolin-2(1H)-one as a specific allosteric inhibitor of Akt. <i>Scientific Reports</i> , 2017, 7, 11673.	3.3	5
28	Discovery and Optimization of Potent, Cell-Active Pyrazole-Based Inhibitors of Lactate Dehydrogenase (LDH). <i>Journal of Medicinal Chemistry</i> , 2017, 60, 9184-9204.	6.4	98
29	MCOLN1 is a ROS sensor in lysosomes that regulates autophagy. <i>Nature Communications</i> , 2016, 7, 12109.	12.8	369
30	Structural Insights into the Activation of Human Relaxin Family Peptide Receptor 1 by Small-Molecule Agonists. <i>Biochemistry</i> , 2016, 55, 1772-1783.	2.5	22
31	Discovery, Optimization, and Characterization of Novel Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 841-853.	6.4	30
32	Discovery of NCT-501, a Potent and Selective Theophylline-Based Inhibitor of Aldehyde Dehydrogenase 1A1 (ALDH1A1). <i>Journal of Medicinal Chemistry</i> , 2015, 58, 5967-5978.	6.4	52
33	Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection. <i>Science Translational Medicine</i> , 2015, 7, 282ra49.	12.4	118
34	Identification of novel anti-hepatitis C virus agents by a quantitative high throughput screen in a cell-based infection assay. <i>Antiviral Research</i> , 2015, 124, 20-29.	4.1	9
35	High-Throughput Screening, Discovery, and Optimization To Develop a Benzofuran Class of Hepatitis C Virus Inhibitors. <i>ACS Combinatorial Science</i> , 2015, 17, 641-652.	3.8	23
36	Structural insight into exosite binding and discovery of novel exosite inhibitors of botulinum neurotoxin serotype A through in silico screening. <i>Journal of Computer-Aided Molecular Design</i> , 2014, 28, 765-778.	2.9	14

#	ARTICLE	IF	CITATIONS
37	Structure-activity relationship studies and biological characterization of human NAD ⁺ -dependent 15-hydroxyprostaglandin dehydrogenase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 630-635.	2.2	13
38	Inhibitors of the <i>Yersinia</i> protein tyrosine phosphatase through high throughput and virtual screening approaches. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 1056-1062.	2.2	12